| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myocardium | 24 | 2019 | 592 | 2.420 |
Why?
|
| Heart-Assist Devices | 14 | 2016 | 898 | 2.100 |
Why?
|
| Receptors, Adrenergic, beta | 15 | 2018 | 73 | 2.090 |
Why?
|
| Coronary Artery Bypass | 8 | 2025 | 252 | 2.050 |
Why?
|
| Platelet Aggregation Inhibitors | 3 | 2022 | 180 | 1.400 |
Why?
|
| Heart Failure | 19 | 2019 | 1422 | 1.340 |
Why?
|
| G-Protein-Coupled Receptor Kinase 2 | 7 | 2015 | 24 | 1.300 |
Why?
|
| Ventricular Remodeling | 4 | 2019 | 114 | 1.160 |
Why?
|
| Polyethylene Glycols | 3 | 2018 | 376 | 1.140 |
Why?
|
| Heart | 9 | 2011 | 590 | 1.040 |
Why?
|
| Arrestins | 3 | 2015 | 11 | 1.030 |
Why?
|
| Platelet Function Tests | 2 | 2022 | 11 | 0.940 |
Why?
|
| Heart Transplantation | 10 | 2016 | 811 | 0.920 |
Why?
|
| Signal Transduction | 16 | 2019 | 3581 | 0.900 |
Why?
|
| Thoracic Surgery | 1 | 2025 | 62 | 0.830 |
Why?
|
| Oxidative Stress | 3 | 2015 | 473 | 0.820 |
Why?
|
| Brain Death | 7 | 2014 | 88 | 0.810 |
Why?
|
| Myocardial Reperfusion Injury | 4 | 2014 | 59 | 0.800 |
Why?
|
| Fellowships and Scholarships | 1 | 2025 | 145 | 0.790 |
Why?
|
| Patient Readmission | 4 | 2016 | 413 | 0.750 |
Why?
|
| Heart Ventricles | 8 | 2011 | 810 | 0.720 |
Why?
|
| Fibroblasts | 6 | 2019 | 777 | 0.720 |
Why?
|
| Myocytes, Cardiac | 6 | 2019 | 323 | 0.690 |
Why?
|
| Thrombelastography | 1 | 2021 | 48 | 0.690 |
Why?
|
| Apoptosis | 5 | 2018 | 1756 | 0.680 |
Why?
|
| beta-Adrenergic Receptor Kinases | 9 | 2006 | 11 | 0.620 |
Why?
|
| Ventricular Function | 2 | 2011 | 55 | 0.610 |
Why?
|
| NADPH Oxidases | 2 | 2015 | 85 | 0.570 |
Why?
|
| Myofibroblasts | 3 | 2019 | 51 | 0.560 |
Why?
|
| Prosthesis-Related Infections | 2 | 2015 | 60 | 0.550 |
Why?
|
| Prosthesis Implantation | 2 | 2015 | 131 | 0.520 |
Why?
|
| Tricuspid Valve | 2 | 2014 | 112 | 0.480 |
Why?
|
| Postoperative Complications | 10 | 2025 | 2592 | 0.470 |
Why?
|
| Myocardial Infarction | 2 | 2019 | 429 | 0.460 |
Why?
|
| Internship and Residency | 1 | 2025 | 1134 | 0.460 |
Why?
|
| Male | 46 | 2025 | 45684 | 0.450 |
Why?
|
| Mitochondria | 2 | 2015 | 621 | 0.440 |
Why?
|
| Fibrillar Collagens | 1 | 2014 | 10 | 0.440 |
Why?
|
| Cardiac Valve Annuloplasty | 1 | 2014 | 15 | 0.420 |
Why?
|
| Rats | 10 | 2019 | 4154 | 0.420 |
Why?
|
| Hemorrhage | 1 | 2016 | 294 | 0.410 |
Why?
|
| Myocardial Contraction | 14 | 2014 | 253 | 0.410 |
Why?
|
| Humans | 57 | 2025 | 95795 | 0.410 |
Why?
|
| Caspase 3 | 4 | 2018 | 164 | 0.410 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 8 | 2000 | 112 | 0.400 |
Why?
|
| Receptors, Adrenergic, beta-2 | 5 | 2008 | 39 | 0.400 |
Why?
|
| Collagen | 2 | 2015 | 306 | 0.400 |
Why?
|
| Recovery of Function | 5 | 2017 | 348 | 0.390 |
Why?
|
| Ventricular Function, Left | 7 | 2018 | 662 | 0.390 |
Why?
|
| Snoring | 1 | 2013 | 12 | 0.390 |
Why?
|
| Heart Arrest, Induced | 3 | 2017 | 30 | 0.390 |
Why?
|
| Length of Stay | 5 | 2017 | 833 | 0.390 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2012 | 48 | 0.380 |
Why?
|
| Saphenous Vein | 1 | 2012 | 61 | 0.380 |
Why?
|
| Organ Preservation Solutions | 2 | 2014 | 35 | 0.380 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2012 | 84 | 0.380 |
Why?
|
| Middle Aged | 31 | 2025 | 28207 | 0.370 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2014 | 129 | 0.370 |
Why?
|
| Retrospective Studies | 20 | 2025 | 10273 | 0.360 |
Why?
|
| Propanolamines | 3 | 2008 | 18 | 0.360 |
Why?
|
| Protein Kinase C-alpha | 2 | 2010 | 29 | 0.350 |
Why?
|
| beta-Arrestins | 3 | 2015 | 9 | 0.350 |
Why?
|
| Female | 36 | 2025 | 49870 | 0.340 |
Why?
|
| Adrenergic beta-Antagonists | 3 | 2008 | 110 | 0.340 |
Why?
|
| Pericardium | 1 | 2011 | 73 | 0.330 |
Why?
|
| Phosphorylation | 6 | 2020 | 1156 | 0.330 |
Why?
|
| Cardiopulmonary Bypass | 3 | 2017 | 162 | 0.330 |
Why?
|
| Hospital Costs | 3 | 2025 | 117 | 0.320 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2010 | 7 | 0.320 |
Why?
|
| Cardiotonic Agents | 3 | 2012 | 95 | 0.320 |
Why?
|
| Animals | 34 | 2019 | 28887 | 0.310 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2013 | 220 | 0.310 |
Why?
|
| Incidence | 8 | 2025 | 1714 | 0.310 |
Why?
|
| Janus Kinase 2 | 1 | 2010 | 59 | 0.310 |
Why?
|
| Membrane Glycoproteins | 4 | 2015 | 453 | 0.310 |
Why?
|
| STAT3 Transcription Factor | 1 | 2010 | 89 | 0.310 |
Why?
|
| Sodium-Hydrogen Exchangers | 4 | 2002 | 78 | 0.300 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2017 | 340 | 0.300 |
Why?
|
| Coronary Vessels | 1 | 2011 | 201 | 0.300 |
Why?
|
| Time Factors | 13 | 2023 | 5561 | 0.300 |
Why?
|
| Treatment Outcome | 15 | 2023 | 9167 | 0.300 |
Why?
|
| GTP-Binding Proteins | 6 | 2006 | 148 | 0.300 |
Why?
|
| Cells, Cultured | 6 | 2015 | 2929 | 0.290 |
Why?
|
| Catheterization | 1 | 2010 | 237 | 0.290 |
Why?
|
| Smoking | 1 | 2012 | 649 | 0.290 |
Why?
|
| Nitric Oxide | 1 | 2010 | 281 | 0.280 |
Why?
|
| Acute Kidney Injury | 3 | 2023 | 340 | 0.280 |
Why?
|
| Postoperative Care | 3 | 2016 | 238 | 0.280 |
Why?
|
| RNA, Messenger | 3 | 2012 | 2089 | 0.280 |
Why?
|
| Aortic Aneurysm, Thoracic | 2 | 2021 | 98 | 0.280 |
Why?
|
| Stress, Physiological | 1 | 2010 | 252 | 0.270 |
Why?
|
| Cyclic AMP | 5 | 2015 | 283 | 0.270 |
Why?
|
| Organ Preservation | 2 | 2008 | 130 | 0.270 |
Why?
|
| Intraoperative Complications | 1 | 2008 | 197 | 0.260 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2019 | 1267 | 0.260 |
Why?
|
| Aged | 21 | 2025 | 20847 | 0.250 |
Why?
|
| Gene Expression Regulation | 3 | 2012 | 2061 | 0.250 |
Why?
|
| Molecular Weight | 2 | 2018 | 329 | 0.250 |
Why?
|
| Mice, Transgenic | 13 | 2010 | 1645 | 0.240 |
Why?
|
| Receptors, Adrenergic, beta-1 | 1 | 2006 | 8 | 0.240 |
Why?
|
| Isoproterenol | 5 | 2015 | 62 | 0.240 |
Why?
|
| Oxygen | 1 | 2011 | 781 | 0.240 |
Why?
|
| NADPH Oxidase 4 | 2 | 2015 | 15 | 0.240 |
Why?
|
| Cardiac Surgical Procedures | 3 | 2017 | 514 | 0.240 |
Why?
|
| Survival Rate | 6 | 2017 | 1971 | 0.230 |
Why?
|
| Endocarditis | 1 | 2025 | 25 | 0.230 |
Why?
|
| Coronary Artery Disease | 3 | 2023 | 394 | 0.230 |
Why?
|
| Histiocytoma, Benign Fibrous | 1 | 2004 | 23 | 0.220 |
Why?
|
| Transforming Growth Factor beta | 3 | 2019 | 349 | 0.220 |
Why?
|
| Reperfusion Injury | 1 | 2006 | 148 | 0.220 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2015 | 124 | 0.220 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2025 | 72 | 0.220 |
Why?
|
| Adult | 20 | 2021 | 28578 | 0.220 |
Why?
|
| Heart Neoplasms | 1 | 2004 | 65 | 0.210 |
Why?
|
| Operative Time | 1 | 2025 | 167 | 0.210 |
Why?
|
| Follow-Up Studies | 7 | 2017 | 3904 | 0.200 |
Why?
|
| MAP Kinase Signaling System | 2 | 2014 | 206 | 0.200 |
Why?
|
| Aortic Valve Stenosis | 1 | 2025 | 166 | 0.200 |
Why?
|
| Gene Transfer Techniques | 3 | 1999 | 156 | 0.200 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2022 | 10 | 0.190 |
Why?
|
| Atrial Fibrillation | 3 | 2018 | 392 | 0.190 |
Why?
|
| Risk Factors | 11 | 2025 | 5961 | 0.190 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2002 | 60 | 0.180 |
Why?
|
| Aortic Valve | 2 | 2016 | 273 | 0.180 |
Why?
|
| Coronary Angiography | 1 | 2023 | 261 | 0.180 |
Why?
|
| Receptors, Adrenergic, alpha | 2 | 1999 | 16 | 0.180 |
Why?
|
| Catecholamines | 2 | 2020 | 92 | 0.180 |
Why?
|
| Perfusion | 3 | 2014 | 266 | 0.170 |
Why?
|
| Aging | 1 | 2006 | 766 | 0.170 |
Why?
|
| Blood Platelets | 1 | 2021 | 154 | 0.170 |
Why?
|
| Reactive Oxygen Species | 2 | 2015 | 517 | 0.170 |
Why?
|
| Mitochondria, Heart | 1 | 2020 | 49 | 0.160 |
Why?
|
| Peptide Fragments | 2 | 1999 | 477 | 0.160 |
Why?
|
| Adrenergic beta-Agonists | 3 | 2015 | 75 | 0.160 |
Why?
|
| Surgeons | 1 | 2025 | 298 | 0.160 |
Why?
|
| Swine | 5 | 2008 | 598 | 0.160 |
Why?
|
| Tissue Donors | 3 | 2014 | 542 | 0.160 |
Why?
|
| beta-Arrestin 2 | 1 | 2019 | 5 | 0.150 |
Why?
|
| beta-Arrestin 1 | 1 | 2019 | 6 | 0.150 |
Why?
|
| Mitral Valve | 2 | 2012 | 279 | 0.150 |
Why?
|
| Disease Models, Animal | 7 | 2019 | 2534 | 0.150 |
Why?
|
| Angiotensin II | 2 | 2015 | 95 | 0.150 |
Why?
|
| Mice | 14 | 2010 | 12536 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2017 | 2773 | 0.150 |
Why?
|
| Sensitivity and Specificity | 4 | 2013 | 2039 | 0.140 |
Why?
|
| Caveolin 1 | 1 | 2018 | 25 | 0.140 |
Why?
|
| Nitrates | 1 | 2018 | 36 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2004 | 1463 | 0.140 |
Why?
|
| Cardiovascular Agents | 1 | 2018 | 61 | 0.140 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 1998 | 76 | 0.140 |
Why?
|
| Receptors, Adrenergic, alpha-1 | 1 | 1997 | 7 | 0.140 |
Why?
|
| Cell Line | 4 | 2015 | 2536 | 0.130 |
Why?
|
| Recombinant Proteins | 1 | 1999 | 1006 | 0.130 |
Why?
|
| Interleukin-6 | 2 | 2010 | 281 | 0.130 |
Why?
|
| Rhodopsin | 2 | 2015 | 21 | 0.130 |
Why?
|
| Aortic Diseases | 1 | 2017 | 104 | 0.130 |
Why?
|
| Amiodarone | 1 | 2016 | 15 | 0.130 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2006 | 2473 | 0.130 |
Why?
|
| Aorta, Thoracic | 1 | 2017 | 170 | 0.120 |
Why?
|
| Protein Processing, Post-Translational | 1 | 1999 | 416 | 0.120 |
Why?
|
| Creatinine | 2 | 2014 | 299 | 0.120 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2017 | 630 | 0.120 |
Why?
|
| Aortic Aneurysm | 1 | 2017 | 82 | 0.120 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2016 | 69 | 0.120 |
Why?
|
| Calcium Channels, L-Type | 3 | 2005 | 39 | 0.120 |
Why?
|
| Microscopy, Confocal | 2 | 2015 | 286 | 0.120 |
Why?
|
| Pulsatile Flow | 1 | 2016 | 52 | 0.120 |
Why?
|
| NADPH Oxidase 2 | 1 | 2015 | 22 | 0.120 |
Why?
|
| Acetophenones | 1 | 2015 | 27 | 0.120 |
Why?
|
| Cost-Benefit Analysis | 2 | 2016 | 500 | 0.120 |
Why?
|
| Pneumothorax | 1 | 2016 | 52 | 0.120 |
Why?
|
| Cell Line, Transformed | 1 | 2015 | 156 | 0.120 |
Why?
|
| Equipment Failure | 1 | 2016 | 128 | 0.120 |
Why?
|
| Superoxides | 1 | 2015 | 76 | 0.120 |
Why?
|
| Ileus | 1 | 2015 | 14 | 0.110 |
Why?
|
| Heart Valve Diseases | 2 | 2016 | 121 | 0.110 |
Why?
|
| Silicones | 1 | 2014 | 21 | 0.110 |
Why?
|
| Area Under Curve | 2 | 2013 | 340 | 0.110 |
Why?
|
| Gene Knockdown Techniques | 2 | 2019 | 256 | 0.110 |
Why?
|
| Costs and Cost Analysis | 1 | 2015 | 157 | 0.110 |
Why?
|
| Ambulatory Care | 1 | 2016 | 198 | 0.110 |
Why?
|
| Smad Proteins | 1 | 2014 | 44 | 0.110 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2014 | 124 | 0.110 |
Why?
|
| RNA Interference | 1 | 2015 | 385 | 0.110 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2014 | 71 | 0.110 |
Why?
|
| Intraoperative Period | 1 | 2014 | 98 | 0.110 |
Why?
|
| Adenylyl Cyclases | 3 | 1999 | 106 | 0.110 |
Why?
|
| Global Health | 1 | 2016 | 213 | 0.110 |
Why?
|
| Up-Regulation | 2 | 2015 | 740 | 0.100 |
Why?
|
| Organ Transplantation | 1 | 2017 | 298 | 0.100 |
Why?
|
| Serum Albumin | 1 | 2014 | 127 | 0.100 |
Why?
|
| Glucocorticoids | 2 | 2007 | 369 | 0.100 |
Why?
|
| RNA, Small Interfering | 1 | 2015 | 562 | 0.100 |
Why?
|
| Enzyme Activation | 2 | 2010 | 692 | 0.100 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2014 | 60 | 0.100 |
Why?
|
| Transgenes | 3 | 1999 | 186 | 0.100 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2014 | 83 | 0.100 |
Why?
|
| Pneumonectomy | 1 | 2016 | 217 | 0.100 |
Why?
|
| Cell Survival | 2 | 2014 | 1029 | 0.100 |
Why?
|
| Mitral Valve Annuloplasty | 1 | 2013 | 16 | 0.100 |
Why?
|
| Hypertension, Pulmonary | 2 | 2012 | 381 | 0.100 |
Why?
|
| Heart Atria | 2 | 2014 | 290 | 0.100 |
Why?
|
| Bacterial Infections | 1 | 2014 | 183 | 0.100 |
Why?
|
| ROC Curve | 2 | 2013 | 797 | 0.100 |
Why?
|
| Connexins | 1 | 2014 | 206 | 0.100 |
Why?
|
| Adenoviridae | 3 | 1999 | 342 | 0.100 |
Why?
|
| Sleep, REM | 1 | 2013 | 51 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2014 | 367 | 0.100 |
Why?
|
| Gene Expression | 6 | 2010 | 1319 | 0.100 |
Why?
|
| Sleep Stages | 1 | 2013 | 47 | 0.100 |
Why?
|
| Xanthenes | 1 | 2012 | 23 | 0.100 |
Why?
|
| Raffinose | 2 | 2014 | 24 | 0.100 |
Why?
|
| Luminescent Proteins | 3 | 2002 | 145 | 0.100 |
Why?
|
| Biomarkers | 2 | 2010 | 1931 | 0.100 |
Why?
|
| Genetic Vectors | 3 | 1999 | 446 | 0.090 |
Why?
|
| Hypertrophy, Right Ventricular | 1 | 2012 | 33 | 0.090 |
Why?
|
| Recombinant Fusion Proteins | 4 | 2002 | 564 | 0.090 |
Why?
|
| Receptors, Dopamine D1 | 1 | 2012 | 34 | 0.090 |
Why?
|
| Allopurinol | 2 | 2014 | 77 | 0.090 |
Why?
|
| Glutathione | 2 | 2014 | 107 | 0.090 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2016 | 318 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2020 | 1230 | 0.090 |
Why?
|
| Logistic Models | 2 | 2013 | 1267 | 0.090 |
Why?
|
| Severity of Illness Index | 2 | 2017 | 1981 | 0.090 |
Why?
|
| Down-Regulation | 2 | 2012 | 526 | 0.090 |
Why?
|
| Arousal | 1 | 2013 | 173 | 0.090 |
Why?
|
| Phenylephrine | 2 | 2004 | 36 | 0.090 |
Why?
|
| Heart Diseases | 1 | 2014 | 314 | 0.090 |
Why?
|
| Models, Animal | 2 | 2011 | 286 | 0.090 |
Why?
|
| Preoperative Care | 2 | 2016 | 417 | 0.090 |
Why?
|
| Lung Transplantation | 1 | 2016 | 367 | 0.090 |
Why?
|
| Skin | 1 | 2014 | 605 | 0.090 |
Why?
|
| Mediastinum | 1 | 2011 | 45 | 0.090 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2013 | 209 | 0.080 |
Why?
|
| Membrane Microdomains | 1 | 2011 | 54 | 0.080 |
Why?
|
| Cardiovascular Diseases | 1 | 2017 | 777 | 0.080 |
Why?
|
| Immunoblotting | 2 | 2008 | 279 | 0.080 |
Why?
|
| Transfection | 3 | 2002 | 908 | 0.080 |
Why?
|
| Probability | 2 | 2008 | 364 | 0.080 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2010 | 21 | 0.080 |
Why?
|
| Cohort Studies | 3 | 2016 | 3106 | 0.080 |
Why?
|
| Cell Hypoxia | 1 | 2011 | 187 | 0.080 |
Why?
|
| Tropomyosin | 1 | 2010 | 16 | 0.080 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2010 | 89 | 0.080 |
Why?
|
| Kidney Failure, Chronic | 1 | 2014 | 432 | 0.080 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2010 | 684 | 0.080 |
Why?
|
| Adenosine | 2 | 2014 | 278 | 0.080 |
Why?
|
| Registries | 1 | 2014 | 985 | 0.080 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2010 | 107 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2017 | 883 | 0.080 |
Why?
|
| Suture Techniques | 1 | 2010 | 143 | 0.070 |
Why?
|
| Membrane Proteins | 2 | 2010 | 1275 | 0.070 |
Why?
|
| Proportional Hazards Models | 3 | 2017 | 900 | 0.070 |
Why?
|
| Echocardiography | 1 | 2014 | 1004 | 0.070 |
Why?
|
| Academic Medical Centers | 2 | 2021 | 422 | 0.070 |
Why?
|
| Cell Proliferation | 1 | 2014 | 1753 | 0.070 |
Why?
|
| Chronic Disease | 2 | 2010 | 983 | 0.070 |
Why?
|
| Diglycerides | 2 | 1998 | 23 | 0.070 |
Why?
|
| In Vitro Techniques | 2 | 2008 | 1008 | 0.070 |
Why?
|
| Cardioplegic Solutions | 1 | 2008 | 17 | 0.070 |
Why?
|
| Aged, 80 and over | 4 | 2025 | 7215 | 0.070 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2010 | 248 | 0.070 |
Why?
|
| Atrial Natriuretic Factor | 2 | 1998 | 39 | 0.070 |
Why?
|
| Lymphocytes | 1 | 2010 | 465 | 0.070 |
Why?
|
| Sodium-Hydrogen Exchanger 3 | 3 | 2002 | 33 | 0.070 |
Why?
|
| Cell Differentiation | 1 | 2014 | 1662 | 0.070 |
Why?
|
| Insulin | 2 | 2014 | 1190 | 0.070 |
Why?
|
| Ventricular Function, Right | 2 | 2017 | 160 | 0.060 |
Why?
|
| Coronary Disease | 1 | 2008 | 263 | 0.060 |
Why?
|
| Elective Surgical Procedures | 1 | 2008 | 162 | 0.060 |
Why?
|
| Multivariate Analysis | 3 | 2014 | 1008 | 0.060 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2007 | 76 | 0.060 |
Why?
|
| Immunocompromised Host | 2 | 2004 | 147 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2008 | 908 | 0.060 |
Why?
|
| Ventricular Pressure | 2 | 2014 | 48 | 0.060 |
Why?
|
| Interleukin-10 | 1 | 2007 | 166 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 3639 | 0.060 |
Why?
|
| Methylprednisolone | 1 | 2005 | 68 | 0.060 |
Why?
|
| Wisconsin | 2 | 2016 | 46 | 0.060 |
Why?
|
| Viral Envelope Proteins | 2 | 2002 | 95 | 0.060 |
Why?
|
| Mice, Knockout | 1 | 2010 | 2161 | 0.060 |
Why?
|
| United States | 4 | 2025 | 7764 | 0.060 |
Why?
|
| Caveolins | 1 | 2004 | 4 | 0.050 |
Why?
|
| Mediastinitis | 1 | 2004 | 14 | 0.050 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2004 | 34 | 0.050 |
Why?
|
| Suction | 1 | 2004 | 38 | 0.050 |
Why?
|
| Strongyloidiasis | 1 | 2004 | 6 | 0.050 |
Why?
|
| Cell Membrane | 3 | 2002 | 687 | 0.050 |
Why?
|
| Therapeutic Irrigation | 1 | 2004 | 66 | 0.050 |
Why?
|
| Sternum | 1 | 2004 | 37 | 0.050 |
Why?
|
| Algorithms | 1 | 2013 | 2015 | 0.050 |
Why?
|
| Debridement | 1 | 2004 | 60 | 0.050 |
Why?
|
| Cardiomegaly | 1 | 2004 | 122 | 0.050 |
Why?
|
| Prosthesis Design | 2 | 2015 | 310 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2007 | 712 | 0.050 |
Why?
|
| Protein Kinase C | 2 | 2004 | 265 | 0.050 |
Why?
|
| Opossums | 1 | 2002 | 5 | 0.050 |
Why?
|
| Intracellular Fluid | 1 | 2002 | 34 | 0.050 |
Why?
|
| Microvilli | 1 | 2002 | 44 | 0.050 |
Why?
|
| Cell Compartmentation | 1 | 2002 | 70 | 0.050 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2002 | 266 | 0.050 |
Why?
|
| Macromolecular Substances | 1 | 2002 | 179 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2004 | 787 | 0.050 |
Why?
|
| Androstadienes | 1 | 2002 | 74 | 0.050 |
Why?
|
| Actins | 2 | 2019 | 472 | 0.050 |
Why?
|
| Endosomes | 1 | 2002 | 86 | 0.050 |
Why?
|
| Disease Progression | 2 | 2017 | 1559 | 0.050 |
Why?
|
| Patient Selection | 2 | 2016 | 708 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2002 | 326 | 0.050 |
Why?
|
| Surgical Wound Infection | 1 | 2004 | 237 | 0.040 |
Why?
|
| Medicare | 1 | 2025 | 458 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2023 | 140 | 0.040 |
Why?
|
| Staphylococcal Infections | 1 | 2004 | 289 | 0.040 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2002 | 509 | 0.040 |
Why?
|
| Stroke Volume | 3 | 2017 | 531 | 0.040 |
Why?
|
| Virulence Factors, Bordetella | 2 | 1999 | 26 | 0.040 |
Why?
|
| Pertussis Toxin | 2 | 1999 | 32 | 0.040 |
Why?
|
| Monoamine Oxidase | 1 | 2020 | 25 | 0.040 |
Why?
|
| Protein Transport | 1 | 2002 | 439 | 0.040 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2020 | 17 | 0.040 |
Why?
|
| Fluorescent Dyes | 1 | 2002 | 262 | 0.040 |
Why?
|
| Cardiac Output | 1 | 2001 | 159 | 0.040 |
Why?
|
| Drug Administration Schedule | 2 | 2016 | 857 | 0.040 |
Why?
|
| CD8 Antigens | 1 | 2000 | 84 | 0.040 |
Why?
|
| Rabbits | 2 | 2000 | 639 | 0.040 |
Why?
|
| Viral Proteins | 1 | 2001 | 289 | 0.040 |
Why?
|
| Vidarabine | 1 | 2000 | 146 | 0.040 |
Why?
|
| Cytoplasmic Vesicles | 1 | 2000 | 6 | 0.040 |
Why?
|
| Feasibility Studies | 2 | 1999 | 816 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2014 | 1957 | 0.040 |
Why?
|
| Sodium Fluoride | 1 | 1999 | 3 | 0.040 |
Why?
|
| Hepatitis C | 1 | 2001 | 184 | 0.040 |
Why?
|
| Epidermal Growth Factor | 1 | 2000 | 116 | 0.040 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2023 | 258 | 0.040 |
Why?
|
| Enzyme Induction | 1 | 1999 | 87 | 0.040 |
Why?
|
| Second Messenger Systems | 1 | 1999 | 42 | 0.040 |
Why?
|
| Oxidation-Reduction | 1 | 2020 | 411 | 0.040 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2000 | 150 | 0.040 |
Why?
|
| Collagen Type I | 1 | 2019 | 74 | 0.040 |
Why?
|
| Heart Rate | 4 | 2007 | 518 | 0.040 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 1998 | 159 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2004 | 847 | 0.040 |
Why?
|
| Inositol Phosphates | 1 | 1998 | 16 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 1998 | 76 | 0.030 |
Why?
|
| COS Cells | 1 | 1998 | 168 | 0.030 |
Why?
|
| Gene Targeting | 1 | 1998 | 78 | 0.030 |
Why?
|
| Adenylate Cyclase Toxin | 1 | 1997 | 14 | 0.030 |
Why?
|
| Sarcolemma | 1 | 1997 | 32 | 0.030 |
Why?
|
| Tachycardia | 1 | 1997 | 36 | 0.030 |
Why?
|
| Cardiac Catheterization | 1 | 1999 | 330 | 0.030 |
Why?
|
| Myocardial Ischemia | 1 | 1998 | 167 | 0.030 |
Why?
|
| Coronary Artery Bypass, Off-Pump | 1 | 2017 | 42 | 0.030 |
Why?
|
| Organ Size | 1 | 2017 | 376 | 0.030 |
Why?
|
| Propensity Score | 1 | 2017 | 180 | 0.030 |
Why?
|
| Protein Isoforms | 2 | 2010 | 296 | 0.030 |
Why?
|
| Genetic Therapy | 1 | 1999 | 382 | 0.030 |
Why?
|
| Calcium | 3 | 2010 | 1205 | 0.030 |
Why?
|
| Adaptation, Physiological | 1 | 1999 | 340 | 0.030 |
Why?
|
| Random Allocation | 2 | 2007 | 321 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2013 | 1739 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2000 | 705 | 0.030 |
Why?
|
| Cost Savings | 1 | 2016 | 71 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2000 | 760 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2023 | 2480 | 0.030 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2017 | 167 | 0.030 |
Why?
|
| India | 1 | 2016 | 138 | 0.030 |
Why?
|
| Intestinal Mucosa | 1 | 2000 | 825 | 0.030 |
Why?
|
| G-Protein-Coupled Receptor Kinase 5 | 3 | 2001 | 6 | 0.030 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2016 | 197 | 0.030 |
Why?
|
| Cold Ischemia | 1 | 2014 | 22 | 0.030 |
Why?
|
| Metabolic Clearance Rate | 1 | 2014 | 119 | 0.030 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2016 | 362 | 0.030 |
Why?
|
| Warm Ischemia | 1 | 2014 | 33 | 0.030 |
Why?
|
| Hemodynamics | 3 | 2005 | 775 | 0.030 |
Why?
|
| Connexin 43 | 1 | 2014 | 94 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2014 | 4664 | 0.030 |
Why?
|
| Gap Junctions | 1 | 2014 | 147 | 0.030 |
Why?
|
| Lung Diseases | 1 | 2016 | 288 | 0.030 |
Why?
|
| Bangladesh | 1 | 2014 | 339 | 0.030 |
Why?
|
| Cadherins | 1 | 2014 | 179 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2014 | 318 | 0.020 |
Why?
|
| Lung | 1 | 1999 | 1380 | 0.020 |
Why?
|
| Dobutamine | 1 | 2012 | 62 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2014 | 480 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 1194 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2012 | 96 | 0.020 |
Why?
|
| Fatal Outcome | 2 | 2004 | 303 | 0.020 |
Why?
|
| Models, Economic | 1 | 2012 | 62 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 362 | 0.020 |
Why?
|
| Comorbidity | 1 | 2015 | 1011 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2014 | 996 | 0.020 |
Why?
|
| Dopamine | 1 | 2012 | 283 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2014 | 829 | 0.020 |
Why?
|
| Hepatitis A Virus Cellular Receptor 1 | 1 | 2010 | 17 | 0.020 |
Why?
|
| Lipocalin-2 | 1 | 2010 | 39 | 0.020 |
Why?
|
| Lipocalins | 1 | 2010 | 34 | 0.020 |
Why?
|
| Cystatin C | 1 | 2010 | 29 | 0.020 |
Why?
|
| Acute-Phase Proteins | 1 | 2010 | 36 | 0.020 |
Why?
|
| Prevalence | 1 | 2014 | 1349 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 701 | 0.020 |
Why?
|
| Receptors, Virus | 1 | 2010 | 77 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 2 | 2001 | 314 | 0.020 |
Why?
|
| Age Factors | 1 | 2015 | 1957 | 0.020 |
Why?
|
| Glutathione Transferase | 1 | 2010 | 116 | 0.020 |
Why?
|
| Cricetulus | 2 | 2000 | 132 | 0.020 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2010 | 86 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2012 | 713 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 1877 | 0.020 |
Why?
|
| Isomerism | 1 | 2010 | 30 | 0.020 |
Why?
|
| Myofibrils | 1 | 2010 | 21 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2010 | 137 | 0.020 |
Why?
|
| Dimerization | 1 | 2010 | 150 | 0.020 |
Why?
|
| Cricetinae | 2 | 2000 | 542 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2012 | 483 | 0.020 |
Why?
|
| Patient Discharge | 1 | 2012 | 361 | 0.020 |
Why?
|
| Reference Values | 2 | 2001 | 674 | 0.020 |
Why?
|
| Temperature | 1 | 2010 | 426 | 0.020 |
Why?
|
| Actin Cytoskeleton | 1 | 2010 | 201 | 0.020 |
Why?
|
| Homeostasis | 1 | 2010 | 467 | 0.020 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2016 | 1145 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2014 | 771 | 0.020 |
Why?
|
| I-kappa B Proteins | 1 | 2007 | 54 | 0.020 |
Why?
|
| Calmodulin | 1 | 2005 | 51 | 0.010 |
Why?
|
| Amino Acid Motifs | 1 | 2005 | 123 | 0.010 |
Why?
|
| Systole | 1 | 2005 | 116 | 0.010 |
Why?
|
| Diastole | 1 | 2005 | 147 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2005 | 297 | 0.010 |
Why?
|
| Caveolin 3 | 1 | 2004 | 4 | 0.010 |
Why?
|
| Benzophenanthridines | 1 | 2004 | 22 | 0.010 |
Why?
|
| Phenanthridines | 1 | 2004 | 24 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 2004 | 63 | 0.010 |
Why?
|
| Staurosporine | 1 | 2004 | 34 | 0.010 |
Why?
|
| Alkaloids | 1 | 2004 | 47 | 0.010 |
Why?
|
| Chest Tubes | 1 | 2004 | 21 | 0.010 |
Why?
|
| Immunohistochemistry | 2 | 1999 | 1827 | 0.010 |
Why?
|
| Candidiasis | 1 | 2004 | 39 | 0.010 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2004 | 133 | 0.010 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2004 | 153 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2005 | 750 | 0.010 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2004 | 62 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2007 | 469 | 0.010 |
Why?
|
| Syndrome | 1 | 2004 | 450 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2016 | 2386 | 0.010 |
Why?
|
| Prognosis | 1 | 2010 | 3990 | 0.010 |
Why?
|
| Feces | 1 | 2004 | 360 | 0.010 |
Why?
|
| Cell Membrane Permeability | 1 | 2001 | 121 | 0.010 |
Why?
|
| Adolescent | 1 | 2014 | 9873 | 0.010 |
Why?
|
| Receptors, IgE | 1 | 2000 | 6 | 0.010 |
Why?
|
| CD5 Antigens | 1 | 2000 | 13 | 0.010 |
Why?
|
| Action Potentials | 1 | 2004 | 618 | 0.010 |
Why?
|
| Antigens, CD20 | 1 | 2000 | 33 | 0.010 |
Why?
|
| Antigens, CD19 | 1 | 2000 | 78 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2001 | 1046 | 0.010 |
Why?
|
| Biotin | 1 | 1999 | 46 | 0.010 |
Why?
|
| Rats, Inbred LEC | 1 | 1999 | 1 | 0.010 |
Why?
|
| Monocrotaline | 1 | 1999 | 13 | 0.010 |
Why?
|
| Bone Marrow Cells | 1 | 2000 | 270 | 0.010 |
Why?
|
| Ethanolamines | 1 | 1999 | 24 | 0.010 |
Why?
|
| Colforsin | 1 | 1999 | 75 | 0.010 |
Why?
|
| Pulmonary Circulation | 1 | 1999 | 92 | 0.010 |
Why?
|
| Biological Transport | 1 | 1999 | 412 | 0.010 |
Why?
|
| Thionucleotides | 1 | 1999 | 56 | 0.010 |
Why?
|
| Models, Biological | 1 | 2005 | 1809 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2000 | 726 | 0.010 |
Why?
|
| Norepinephrine | 1 | 1999 | 173 | 0.010 |
Why?
|
| Graft Rejection | 1 | 2004 | 1126 | 0.010 |
Why?
|
| Transplantation, Heterotopic | 1 | 1998 | 48 | 0.010 |
Why?
|
| Lac Operon | 1 | 1998 | 46 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 1998 | 70 | 0.010 |
Why?
|
| Blotting, Western | 1 | 1999 | 796 | 0.010 |
Why?
|
| Imidazoles | 1 | 1999 | 144 | 0.010 |
Why?
|
| Dogs | 1 | 1999 | 718 | 0.010 |
Why?
|
| Rats, Inbred Strains | 1 | 1998 | 311 | 0.010 |
Why?
|
| Luciferases | 1 | 1998 | 130 | 0.010 |
Why?
|
| Calcium Channels | 1 | 1999 | 183 | 0.010 |
Why?
|
| Myosin Heavy Chains | 1 | 1998 | 91 | 0.010 |
Why?
|
| Cattle | 1 | 1998 | 385 | 0.010 |
Why?
|
| Receptors, Angiotensin | 1 | 1996 | 11 | 0.010 |
Why?
|
| Phenotype | 1 | 1996 | 2575 | 0.000 |
Why?
|
| Antineoplastic Agents | 1 | 2000 | 2383 | 0.000 |
Why?
|